6.98
price up icon4.18%   0.28
after-market アフターアワーズ: 7.12 0.14 +2.01%
loading
前日終値:
$6.70
開ける:
$6.78
24時間の取引高:
506.25K
Relative Volume:
0.51
時価総額:
$464.87M
収益:
$80.00M
当期純損益:
$-74.88M
株価収益率:
-5.9092
EPS:
-1.1812
ネットキャッシュフロー:
$-60.38M
1週間 パフォーマンス:
+0.87%
1か月 パフォーマンス:
-22.27%
6か月 パフォーマンス:
-17.88%
1年 パフォーマンス:
+124.44%
1日の値動き範囲:
Value
$6.78
$7.16
1週間の範囲:
Value
$6.56
$7.16
52週間の値動き範囲:
Value
$2.315
$15.74

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name
名前
Fulcrum Therapeutics Inc
Name
セクター
Healthcare (1114)
Name
電話
617-651-8851
Name
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
職員
55
Name
Twitter
@fulcrumtx
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
FULC's Discussions on Twitter

Compare FULC vs VRTX, REGN, ALNY, ARGX, INSM

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
FULC icon
FULC
Fulcrum Therapeutics Inc
6.98 446.22M 80.00M -74.88M -60.38M -1.1812
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
454.97 113.96B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
749.47 78.41B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
328.70 40.85B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
697.05 42.05B 4.16B 1.29B 734.26M 19.58
INSM icon
INSM
Insmed Inc
148.31 29.99B 606.42M -1.28B -997.58M -6.403

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-12 開始されました JP Morgan Overweight
2025-11-24 開始されました Truist Buy
2025-07-29 アップグレード H.C. Wainwright Neutral → Buy
2025-05-23 アップグレード Leerink Partners Market Perform → Outperform
2025-05-15 アップグレード Cantor Fitzgerald Neutral → Overweight
2024-09-13 ダウングレード H.C. Wainwright Buy → Neutral
2024-09-12 ダウングレード BofA Securities Neutral → Underperform
2024-09-12 ダウングレード Cantor Fitzgerald Overweight → Neutral
2024-09-12 ダウングレード Leerink Partners Outperform → Market Perform
2024-09-12 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2024-09-12 ダウングレード Stifel Buy → Hold
2024-09-09 アップグレード BofA Securities Underperform → Neutral
2024-05-20 開始されました Cantor Fitzgerald Overweight
2024-03-13 開始されました RBC Capital Mkts Outperform
2023-09-25 開始されました Goldman Neutral
2023-08-23 アップグレード H.C. Wainwright Neutral → Buy
2023-08-22 アップグレード Stifel Hold → Buy
2023-05-04 ダウングレード Goldman Buy → Neutral
2023-03-10 ダウングレード Credit Suisse Outperform → Neutral
2023-03-10 ダウングレード H.C. Wainwright Buy → Neutral
2023-03-09 ダウングレード Stifel Buy → Hold
2023-02-28 ダウングレード Morgan Stanley Overweight → Equal-Weight
2023-02-24 ダウングレード BofA Securities Neutral → Underperform
2022-11-15 開始されました Goldman Buy
2022-03-08 開始されました Oppenheimer Outperform
2022-03-03 アップグレード BofA Securities Underperform → Neutral
2021-08-11 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-04-26 再開されました Credit Suisse Outperform
2021-03-22 開始されました Credit Suisse Outperform
2021-03-02 開始されました Stifel Buy
2020-10-16 開始されました Piper Sandler Overweight
2020-08-12 ダウングレード BofA Securities Neutral → Underperform
2020-08-12 繰り返されました H.C. Wainwright Buy
2020-08-12 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-06-19 ダウングレード BofA/Merrill Buy → Neutral
2020-06-17 開始されました BTIG Research Buy
2019-10-03 開始されました H.C. Wainwright Buy
2019-08-12 開始されました BofA/Merrill Buy
すべてを表示

Fulcrum Therapeutics Inc (FULC) 最新ニュース

pulisher
Mar 25, 2026

S P Trends: What hedge funds are buying Fulcrum Therapeutics Inc2026 Big Picture & Real-Time Stock Entry Alerts - baoquankhu1.vn

Mar 25, 2026
pulisher
Mar 25, 2026

Institution Moves: Is Fulcrum Therapeutics Inc forming higher highs and higher lows2026 Earnings Surprises & Weekly Market Pulse Updates - baoquankhu1.vn

Mar 25, 2026
pulisher
Mar 22, 2026

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com

Mar 22, 2026
pulisher
Mar 22, 2026

Growth Value: What hedge funds are buying Fulcrum Therapeutics IncMarket Sentiment Report & AI Powered Buy/Sell Recommendations - baoquankhu1.vn

Mar 22, 2026
pulisher
Mar 21, 2026

Profit Recap: Can Fulcrum Therapeutics Inc deliver alpha2026 Retail & Weekly Return Optimization Alerts - baoquankhu1.vn

Mar 21, 2026
pulisher
Mar 20, 2026

Fulcrum Extends Pociredir Program With Long-Term Sickle Cell Study - TipRanks

Mar 20, 2026
pulisher
Mar 19, 2026

Is Fulcrum Therapeutics Inc benefiting from innovation trends2026 Closing Moves & Stepwise Swing Trade Plans - baoquankhu1.vn

Mar 19, 2026
pulisher
Mar 19, 2026

MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease - The Manila Times

Mar 19, 2026
pulisher
Mar 19, 2026

MedicAlert Foundation, Sickle Cell Disease Association of - GlobeNewswire

Mar 19, 2026
pulisher
Mar 16, 2026

Fulcrum Therapeutics Touts PIONEER HbF Gains, Early VOC Signal; FDA Path and Accelerated Approval Talk - MarketBeat

Mar 16, 2026
pulisher
Mar 16, 2026

Short Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Rises By 19.7% - MarketBeat

Mar 16, 2026
pulisher
Mar 16, 2026

Boothbay Fund Management Increases Stake in Fulcrum Therapeutics - National Today

Mar 16, 2026
pulisher
Mar 16, 2026

Fulcrum Therapeutics, Inc. $FULC Shares Bought by Boothbay Fund Management LLC - MarketBeat

Mar 16, 2026
pulisher
Mar 15, 2026

Wall Street analysts think Fulcrum Therapeutics (FULC) could surge 58.47%: Read this before placing a bet - MSN

Mar 15, 2026
pulisher
Mar 15, 2026

219,488 Shares in Fulcrum Therapeutics, Inc. $FULC Bought by Braidwell LP - MarketBeat

Mar 15, 2026
pulisher
Mar 14, 2026

Suvretta Capital Management LLC Raises Holdings in Fulcrum Therapeutics, Inc. $FULC - MarketBeat

Mar 14, 2026
pulisher
Mar 14, 2026

Whats next for Fulcrum Therapeutics Inc stock2026 Winners & Losers & Free Technical Pattern Based Buy Signals - baoquankhu1.vn

Mar 14, 2026
pulisher
Mar 12, 2026

Aug Macro: What’s next for Fulcrum Therapeutics Inc. stock2026 EndofYear Setup & Free Verified High Yield Trade Plans - baoquankhu1.vn

Mar 12, 2026
pulisher
Mar 11, 2026

Fulcrum Therapeutics at Leerink Conference: Strategic Focus on Sickle Cell - Investing.com India

Mar 11, 2026
pulisher
Mar 10, 2026

Fulcrum Therapeutics at Leerink Conference: Strategic Focus on Sickle Cell By Investing.com - Investing.com Canada

Mar 10, 2026
pulisher
Mar 10, 2026

FULC: Pivotal study planned after robust PIONEER results, with focus on severe sickle cell and U.S. launch - TradingView

Mar 10, 2026
pulisher
Mar 10, 2026

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Mar 10, 2026
pulisher
Mar 10, 2026

Fulcrum Therapeutics (FULC) Stock Analysis Report | Financials & Insights - Benzinga Japan

Mar 10, 2026
pulisher
Mar 09, 2026

Fulcrum Therapeutics stock may face pressure on Ipsen withdrawal, Stifel says - Investing.com Canada

Mar 09, 2026
pulisher
Mar 07, 2026

Why Fulcrum Therapeutics Inc. stock appeals to dividend seekersJuly 2025 Highlights & Daily Price Action Insights - Naître et grandir

Mar 07, 2026
pulisher
Mar 07, 2026

Bullish analyst sentiment on Fulcrum Therapeutics (FULC) following positive updates from Phase 1b PIONEER study - MSN

Mar 07, 2026
pulisher
Mar 07, 2026

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 07, 2026
pulisher
Mar 06, 2026

Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Mar 06, 2026
pulisher
Mar 06, 2026

Bull Run: Can Fulcrum Therapeutics Inc disrupt its industryJuly 2025 Price Swings & Reliable Trade Execution Plans - baoquankhu1.vn

Mar 06, 2026
pulisher
Mar 06, 2026

New Fulcrum hire gets 34,000 stock options with 4-year vesting - Stock Titan

Mar 06, 2026
pulisher
Mar 04, 2026

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - 富途牛牛

Mar 04, 2026
pulisher
Mar 04, 2026

Hedge Fund Moves: Is Fulcrum Therapeutics Inc part of any ETFJuly 2025 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn

Mar 04, 2026
pulisher
Mar 03, 2026

FULC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 03, 2026
pulisher
Mar 02, 2026

Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 7.5%Here's Why - MarketBeat

Mar 02, 2026
pulisher
Feb 28, 2026

FULC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Feb 28, 2026
pulisher
Feb 27, 2026

Winners Losers: Can Fulcrum Therapeutics Inc keep up with sector leadersBond Market & Stepwise Swing Trade Plans - baoquankhu1.vn

Feb 27, 2026
pulisher
Feb 27, 2026

What is HC Wainwright’s Forecast for FULC Q1 Earnings? - Defense World

Feb 27, 2026
pulisher
Feb 26, 2026

Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion (NASDAQ:FULC) - Seeking Alpha

Feb 26, 2026
pulisher
Feb 26, 2026

Fulcrum Therapeutics, Inc. (FULC): Analyst Ratings Suggest 111% Upside Potential – Is It Time to Buy? - DirectorsTalk Interviews

Feb 26, 2026
pulisher
Feb 26, 2026

HC Wainwright Has Optimistic Outlook of FULC Q1 Earnings - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

RBC Capital Remains a Hold on Fulcrum Therapeutics (FULC) - The Globe and Mail

Feb 26, 2026
pulisher
Feb 26, 2026

FY2030 Earnings Forecast for FULC Issued By HC Wainwright - Defense World

Feb 26, 2026
pulisher
Feb 25, 2026

Fulcrum Therapeutics move lower ‘overdone,’ says Stifel - Yahoo Finance

Feb 25, 2026
pulisher
Feb 25, 2026

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 25, 2026
pulisher
Feb 25, 2026

H.C. Wainwright Maintains Buy on FULC Fulcrum Therapeutics, Inc. Feb 24, 2026 - Meyka

Feb 25, 2026
pulisher
Feb 25, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Feb 25, 2026
pulisher
Feb 24, 2026

Fulcrum Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Feb 24, 2026
pulisher
Feb 24, 2026

Fulcrum Therapeutics stock falls as sickle cell trial misses target - Investing.com Australia

Feb 24, 2026
pulisher
Feb 24, 2026

Fulcrum Therapeutics stock falls as sickle cell trial misses target By Investing.com - Investing.com Canada

Feb 24, 2026
pulisher
Feb 24, 2026

Leerink reiterates Fulcrum Therapeutics stock rating on SCD data By Investing.com - Investing.com Canada

Feb 24, 2026
pulisher
Feb 24, 2026

Fulcrum Therapeutics shares fall on profit-taking, Oppenheimer says By Investing.com - Investing.com Canada

Feb 24, 2026

Fulcrum Therapeutics Inc (FULC) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$27.36
price up icon 1.82%
$47.03
price up icon 3.20%
$53.54
price up icon 4.29%
$88.77
price up icon 2.26%
ONC ONC
$283.45
price up icon 2.81%
$148.31
price up icon 6.59%
大文字化:     |  ボリューム (24 時間):